naldemedine

Ligand id: 9150

Name: naldemedine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 141.18
Molecular weight 570.25
XLogP 5.03
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes (FDA (2017))
IUPAC Name
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide
International Nonproprietary Names
INN number INN
9484 naldemedine
Synonyms
S-297,995 | S-297995
Database Links
ChEMBL Ligand CHEMBL2105755
GtoPdb PubChem SID 315661235
PubChem CID 54732242
Search Google for chemical match using the InChIKey AXQACEQYCPKDMV-RZAWKFBISA-N
Search Google for chemicals with the same backbone AXQACEQYCPKDMV
Search PubMed clinical trials naldemedine
Search PubMed titles naldemedine
Search PubMed titles/abstracts naldemedine
Search UniChem for chemical match using the InChIKey AXQACEQYCPKDMV-RZAWKFBISA-N
Search UniChem for chemicals with the same backbone AXQACEQYCPKDMV
Wikipedia Naldemedine
Comments
Naldemedine is a μ opioid receptor antagonist, designed to act peripherally (peripherally acting mu-opioid receptor antagonist or PAMORA). It is being investigated for its ability to counteract opioid agonist-induced adverse effects such as constipation, nausea, and vomiting. Naldemedine is being developed by Shionogi Inc. It is the compound claimed in patent WO2013172297 with formula IA (17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid) [1].